New Heart Valve Technology to Feature at TCT 2026
Researchers will present clinical data on a novel heart valve system for patients at the upcoming medical conference.
Updated on Oct. 27, 2026 in Heart Disease
Live Poll
Do you believe new biomimetic heart valve technologies will improve long-term outcomes for aortic stenosis patients?
At the upcoming TCT 2026 conference in San Diego, researchers are scheduled to present new clinical findings on the DurAVR THV system. The presentation on November 1, 2026, will detail 30-day outcomes for patients with the heart valve technology.
Why it matters
This data provides an early look at a novel heart valve system currently under investigation for potential use in treating heart disease. Clinical trials help determine whether new valve designs can safely and effectively manage blood flow in patients.
Clinical results include 30-day hemodynamic outcomes from a cohort of 130 patients enrolled in the EMBARK and Early Feasibility studies. While the underlying ADAPT tissue technology has been used in over 55,000 patients over the last decade, these specific THV performance results remain preliminary.
The players
Azeem Latib
An interventional cardiologist and researcher who will present 30-day clinical outcomes.
Santiago Garcia
An interventional cardiologist who will present on the DurAVR THV system and case-in-a-box technology.
Anteris Technologies
The medical device company that produces the DurAVR THV system and the ADAPT tissue technology.
The details
The DurAVR THV system uses proprietary ADAPT tissue technology designed to maintain structural integrity and hemodynamic function. The valve is deployed via the ComASUR Delivery System, which aims to provide precise placement within the heart. These clinical studies specifically examine the valve's ability to facilitate blood flow and monitor early safety markers during the first 30 days post-procedure.
Timeline
The TCT 2026 conference will be held in San Diego from October 31 to November 3, 2026.
Azeem Latib will present clinical and hemodynamic results on November 1, 2026.
Santiago Garcia will lead a session on the technology on November 3, 2026.
Health Landscape
The development of transcatheter heart valves is a primary focus of global cardiovascular research aimed at reducing the invasiveness of valve replacement procedures. This presentation at the TCT conference updates the clinical record for a device currently moving through the evaluation pipeline.
These preliminary findings are intended for clinical review and do not change current treatment options for patients. Those managing heart valve issues should consult with their cardiologist to discuss standard care options and whether new technologies may be relevant to their future care.
The takeaway
Advancements in valve technology aim to improve patient outcomes through less invasive procedures. Patients should keep track of their cardiac health by attending regular checkups and discussing new developments in valve research with their specialist physician.
Further reading
For more information on the current landscape of valve replacement, visit Heart Disease.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe new biomimetic heart valve technologies will improve long-term outcomes for aortic stenosis patients?
